Sequential protocols with thymoglobuline and delayed introduction of calcineurin: Effects on renal function in renal transplant recipients with non immunological risk and low risk of delayed Graft function;Protocoles séquentiels avec induction par thymoglobulines et introduction retardée des inhibiteurs de la calcineurine: Effets sur la fonction du greffon chez le transplanté rénal sans facteur de risque

Nephrologie

Volumn 25, Issue 4, 2004, Pages 127-132

  Ricard Sutra, E ^a   Garrigue, V ^a   Bismuth, J ^a   Chong, G ^a   Argiles, A ^a   Mourad, Georges ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Antithymocyte globulins; Delayed graft function; Induction therapy; Renal transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; BACTERIAL INFECTION; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; HEMODIALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PROPHYLAXIS; REVIEW;

ADULT; ANTILYMPHOCYTE SERUM; CHILD; CREATININE; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; TACROLIMUS; TREATMENT OUTCOME;

EID: 3042736213     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Bonnefoy-Bernard N, Revillard J-P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15: 435.
2. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60: 1220.
3. Szczech LA, Berlin JA, Aradhyte S, Grossman RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: A metaanalysis. J Am Soc Nephrol 1997; 8: 1771.
4. Mourad G, Portales P, Garrigue V, Djamali A, Bouloux C, Chong G, Clot J. Low-dose antithymocyte globulins in kidney transplantation: Result of a protocol of intermittent administration. Nephrologie 2000; 21: 253-8.
5. Djamali A, Turc-Baron C, Portales P, Leverson G, Chong G, Clot J, Mourad G. Low dose antithymocyte globulins in renal transplantation. Transplantation 2000; 69: 799-805.
6. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus non-induction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001; 72: 1050-5.
7. Yussim A, Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation: A prospective, randomised study. Transpl Int 2000; 13 (Suppl. 1): S293-4.
8. Stratta RJ, D'Alessandro AM, Armbrust MJ, et al. Sequential antilymphocyte globulin/cyclosporin immunosuppression in cadaveric renal transplantation. Transplantation 1989; 47: 96.
9. Olyaei AJ, De Mattos AM, Bennett WM. Neprotoxicity of immunosuppressive drugs: New insight an preventive strategies. Curr Opin Crit Care 2001; 7: 384-9.
10. Govani M, Kwon O, Batiuk T, Milgrom M, Filo R. Creatinine reduction ratio and 24-hour creatinine excretion on posttransplant day two: Simple and objective tools to define graft function. J Am Soc Nephrol 2002; 13: 1645-49.
11. Thibaudin D, Alamartine E, Pierre de Filippis J, et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998, 13: 711-5.
12. Vela C, Cristol JP, Chong G, Okamba A, Lorho R, Mion C, Mourad G. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly renal transplant recipients. Transplant Int 1994; 7 (Suppl. 1): S 259-62.
13. Cantarovich D, Karam G, Giral-classe M, Hourmant M, Dantal J, Blancho G, Le Normand L, Soulillou JP. Randomized comparaison of triple therapy and antithymocyte globulin induction treatement after simultaneous pancreas-kidney transplantation. Kidney Int 1998; 54: 1351-6.
14. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002; 73: 1514-8.
15. Hesse UJ, Troisi R, Jacobs B, Van Vlem B, De Hemptinne B, Van Holder R, Vermassen F, De Rosse J, Lameire N. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin Transplant 2000; 14: 340-4.
16. Reddy KS, Stratta RJ, Shokouh-Amiri H, Alloway R, Somerville T, Egidi MF, Gaber LW, Gaber AO. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation 2000; 69: 49-54.
17. Muller T, Ruffingshofer D, Bidmon B, Arbeiter K, Balzar E, Aufrich C. Reduction of delayed renal allograft function using sequentia immunosuppression. Pediatr Nephrol 2001; 16: 613-7.
18. Ault BH, Honaker MR, Osama Gaber A, Jones DP, Duhart Jr BT, Pow SL, Hays DW, Wyatt RJ. Short-term outcomes of thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 2002; 17: 815-8.
19. No authors listed. A randomised clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1986; 314: 1219-25.
20. English J, Evan A, Hougton DC. Cyclosporin induced acute renal dysfunction in the rat. Transplantation 1987; 44: 135.
21. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-11.
22. Novick AC, Ho-Hsich H, Steinmuller DS, et al. Detrimental effect of cyclosporin on initial function of cadaveric renal allografts following extended preservation results of randomised prospective trial. Transplantation 1986; 42: 154.
23. Lange H, Muller TF, Ebel H, et al. Immediate and long term results of ATG induction therapy for delayed graft function compared with conventional therapy for immediate graft function. Transpl Int 1999; 12: 2-9.
24. Charpentier B. A tree arm study comparing immediate tacrolimus therapy ATG induction therapy followed by either tacrolimus or cyclosporin in adult renal transplant recipients. Transplant Proc 2002; 34: 1625-6.
25. Cole E, Maham N, Cardella C, Fenton S, Hamel J.O'Grady. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation. 2003; 75: 2086-90.
26. Sita Gourishenhan, Gian S. Jhangri, Sanda M. Cockfied, Halloman PF. Donor tissue characteristics influence cadaver kidney transplant function and graft survival but not rejection. JASN 2003; 14: 493-9.